PCM
INSY

Price Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Price Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-8,162
Closed -$237K – 255
2015
Q1 		$237K Buy
+8,162
New +$216K 0.15% 177

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Price Capital Management's INSY Position: Q2 2015 in Review

Price Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q2 2015, closing a stake of 8,162 shares — an estimated $237K sold.

Price Capital Management first reported a position in INSY in Q1 2015 and held it in 1 quarter. The position peaked at $237K in Q1 2015. 146 funds tracked by Wall St. Rank hold INSY as of Q2 2015.

  • Price Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Price Capital Management sold 8,162 Insys Therapeutics, Inc. shares in Q2 2015, an estimated $237K.
  • Price Capital Management first reported a position in Insys Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Price Capital Management's Insys Therapeutics, Inc. position peaked at $237K in Q1 2015.
  • 146 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2015.

Based on Price Capital Management's 13F filing for Q2 2015.